Corvus Pharmaceuticals Inc - Asset Resilience Ratio
Corvus Pharmaceuticals Inc (CRVS) has an Asset Resilience Ratio of 77.65% as of March 2026. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2015–2025)
This chart shows how Corvus Pharmaceuticals Inc's Asset Resilience Ratio has changed over time. Check Corvus Pharmaceuticals Inc (CRVS) strategic asset index to assess the company's strategic physical and investment asset allocation.
Liquid Assets Composition Over Time
This chart breaks down Corvus Pharmaceuticals Inc's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see CRVS market cap overview.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 0% |
| Short-term Investments | $196.61 Million | 77.65% |
| Total Liquid Assets | $196.61 Million | 77.65% |
Asset Resilience Insights
- Very High Liquidity: Corvus Pharmaceuticals Inc maintains exceptional liquid asset reserves at 77.65% of total assets.
- This level provides strong protection against economic uncertainties but may indicate potential for more aggressive growth investments.
- The company has significant short-term investments, indicating active treasury management.
Corvus Pharmaceuticals Inc Industry Peers by Asset Resilience Ratio
Compare Corvus Pharmaceuticals Inc's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Ascendis Pharma AS
NASDAQ:ASND |
Biotechnology | 0.00% |
|
ALTEOGEN Inc
KQ:196170 |
Biotechnology | 55.57% |
|
Apogee Therapeutics, Inc. Common Stock
NASDAQ:APGE |
Biotechnology | 47.01% |
|
Definium Therapeutics, Inc.
NASDAQ:DFTX |
Biotechnology | 34.94% |
|
Neuren Pharmaceuticals Ltd
AU:NEU |
Biotechnology | 90.43% |
|
Galapagos N.V.
AS:GLPG |
Biotechnology | 86.45% |
|
Blue Jet Healthcare Limited
NSE:BLUEJET |
Biotechnology | 13.81% |
|
Inventiva S.A
PA:IVA |
Biotechnology | 52.73% |
Annual Asset Resilience Ratio for Corvus Pharmaceuticals Inc (2015–2025)
The table below shows the annual Asset Resilience Ratio data for Corvus Pharmaceuticals Inc.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2025-12-31 | 73.36% | $52.17 Million | $71.12 Million | +10.63pp |
| 2024-12-31 | 62.73% | $43.22 Million | $68.91 Million | +30.83pp |
| 2023-12-31 | 31.89% | $14.53 Million | $45.55 Million | -10.81pp |
| 2022-12-31 | 42.71% | $29.14 Million | $68.24 Million | +37.23pp |
| 2021-12-31 | 5.48% | $5.99 Million | $109.45 Million | -27.03pp |
| 2020-12-31 | 32.51% | $27.80 Million | $85.53 Million | -54.56pp |
| 2019-12-31 | 87.07% | $72.83 Million | $83.65 Million | +23.29pp |
| 2018-12-31 | 63.77% | $75.40 Million | $118.23 Million | +16.35pp |
| 2017-12-31 | 47.43% | $44.95 Million | $94.78 Million | -45.22pp |
| 2016-12-31 | 92.65% | $129.85 Million | $140.15 Million | +0.95pp |
| 2015-12-31 | 91.69% | $90.28 Million | $98.46 Million | -- |
About Corvus Pharmaceuticals Inc
Corvus Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, engages in the development of product candidates that precisely target proteins that are critical to immune cell maturation and function in the United States. The company's lead product candidate is soquelitinib (CPI-818), a selective covalent inhibitor of interleukin 2 inducible T cell kinase (ITK), which is in a multi-cen… Read more